Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
2005-04-30
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cosopt Versus Xalacom
NCT00273481
Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma
NCT01175902
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
NCT00140049
Assessing Cosopt Switch Patients
NCT00273442
A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin
NCT00759941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
timolol maleate 0.5%
dorzolamide/timolol maleate fixed combination
latanoprost 0.005%
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
* ETDRS visual acuity must be 1.0 or better in both eyes
Exclusion Criteria
* any anticipated change in systemic hypertensive therapy during the trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmaceutical Research Network
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William C. Stewart, MD
Role: STUDY_DIRECTOR
Pharmaceutical Research Network, LLC
Jay Mulaney, MD
Role: PRINCIPAL_INVESTIGATOR
Central Florida Eye Associates
Sriram Sonty, MD, FACS
Role: PRINCIPAL_INVESTIGATOR
Midwest Eye Center SC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Florida Eye Associates
Lakeland, Florida, United States
Midwest Eye Center SC
Bourbonnais, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRN 04-015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.